(secondQuint)Efficacy and Safety Study of Ingavirin 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults.

 Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Ingavirin in the Treatment of Influenza and Other Acute Viral Respiratory Infection.

 Study treatment was 5 days followed by 2 1 days of follow up period.

 Thus, study participation was 7 1 days (8 days max).

.

 Efficacy and Safety Study of Ingavirin 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults@highlight

The purpose of this study is to determine whether Ingavirin(R) 90 mg once daily is effective and safe for the treatment of influenza and other laboratory confirmed acute respiratory viral infections in the course of standard therapy in patients 18-60 years old.

